METASTATIC GASTRIC CANCER

This early-phase study is testing an experimental drug called JNJ-89402638 in people with metastatic colorectal or gastric cancer that has progressed after at least two prior treatments. The trial will first find the safest dose and schedule, then test the drug alone or combined …

This early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…

This study tests a new experimental drug, PF-08634404, combined with chemotherapy in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new…

This early-phase trial is testing a new type of cell therapy called p95HER2.CAR-TECH2Me for people with advanced HER2-positive breast, gastric, or endometrial cancers that have spread. The treatment uses a patient's own immune cells, which are modified in a lab to better recogniz…

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This study tests a two-step treatment for people with advanced liver cancer (hepatocellular carcinoma) or metastatic stomach cancer that has worsened despite prior immunotherapy. First, doctors deliver a drug called tirapazamine directly into the liver tumor through a procedure c…

This study tests a new combination of two experimental drugs (iparomlimab and tuvonralimab, together called QL1706) plus standard chemotherapy in people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. The goal is to see if this combo can…

This early-phase trial tests a personalized vaccine made from a patient's own tumor cells or donor cells. The cells are modified and killed in the lab, then injected under the skin to train the immune system to attack the cancer. The study includes 50 adults with metastatic melan…

This phase 2 trial tests whether adding a daily pill containing a specific gut bacterium (EXL01) to standard immunotherapy (nivolumab) and chemotherapy (FOLFOX) can shrink tumors better than the drugs alone in people with advanced gastric cancer. About 120 participants will be ra…

This Phase 2 trial is testing whether a new targeted drug called SHR2554, taken as a tablet, can be safely combined with other anti-cancer injections to treat advanced stomach or gastroesophageal junction cancer. The study will enroll 351 adults whose cancer has spread or cannot …

This study looks at whether giving the chemotherapy drug paclitaxel over a longer period (2-3 hours instead of 1 hour) can help cancer patients with low muscle mass achieve safer drug levels. Researchers will compare drug concentrations in 22 women with breast, stomach, or esopha…

This study is looking at whether the bacteria in your gut can predict how well a combination of immunotherapy and chemotherapy works for advanced stomach cancer. Researchers will track 300 patients and check their gut bacteria at several points during treatment. The goal is to fi…